

Mirikizumab-mrkz (OMVOH®) Infusion Price Quote

About OMVOH®

OMVOH® is a prescription biologic medication administered via intravenous (IV) infusion by a health care professional and then self-injected for maintenance dosing. The recommended induction dosage is 300 mg administered by intravenous infusion over at least 30 minutes at weeks 0, 4, and 8. The recommended maintenance dosage is 200 mg administered by subcutaneous injection (given as two consecutive injections of 100 mg each) at week 12, and every 4 weeks thereafter.

Indications for Use

OMVOH® is indicated for the treatment of moderately to severely active ulcerative colitis in adults.

Billing

Listed below are the specific billing codes and associated fees for OMVOH® infusions. After you and your MNGI provider decide to begin OMVOH® treatment, MNGI will partner with you in enrolling in any financial assistance programs for which you may be eligible.

The actual allowed amount (the amount of the billed charge deemed payable by an insurance plan) for each charge and the amount of your out-of-pocket expenses will depend on your particular insurance plan. Although Omvoh® Together can help you to determine insurance coverage for OMVOH® treatment, it is important to direct any additional questions you may have regarding coverage and your financial responsibility to your insurer prior to receiving treatment.

If you have any further questions, please contact the Business Office at 612-871-1145.

Billing Code (CPT Code)	Description	Charge Amount
J2267	Inj., mirikizumab-mrkz, 1 mg	\$18,300
96365	IV administration	\$291

Prices may be subject to change